106539-39-3

Upstream product

• 10534-59-5 tetrabutylammonium acetate 
• 84184-35-0 Toluene-4-sulfonic acid 3-benzyloxy-1-methyl-propyl ester 
• 302924-75-0 (R)-((4-(benzyloxy)butan-2-yl)oxy)(tert-butyl)dimethylsilane 
• 108-24-7 acetic anhydride 
• 77564-44-4 (R)-(+)-1,3-butanediol 1-benzyl ether 
• 100-39-0 benzyl bromide 
• 106539-38-2 (3S)-1-benzyloxy-3-(1-ethoxyethoxy)butane 
• 100-44-7 benzyl chloride 
• 4799-69-3 (S)-(-)-1,3-butanediol 1-benzyl ether 

Downstream Products

• 106539-41-7 3(S)-1-benzyloxy-3-phtalimidobutane 
• 77564-44-4 (R)-(+)-1,3-butanediol 1-benzyl ether 

Relevant academic research and scientific papers

ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER

Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.

MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME

Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.

Stereospecific Synthesis of (2R,5R)-Hept-6-yne-2,5-diamine: A Potent and Selective Enzyme-activated Irreversible Inhibitor of Ornithine Decarboxylase (ODC)

Hept-6-yne-2,5-diamine (2) and 2-methylhept-6-yne-2,5-diamine (3), while structurally related to the potent ornithine decarboxylase (ODC) inhibitor hex-5-yne-1,4-diamine (1), are stable to in vivo oxidation by monoamine oxidase (MAO).Although the methyl substitution is at a carbon relatively remote from the site of metabolic attack by ornithine decarboxylase (ODC), it has a critical influence on the potencies of these compounds as inhibitors of the enzyme.Of the four stereoisomers, (2R,5R)-(2) is the most active.Unambiguous syntheses of each isomer of (2) from the dianion of 3-trimethylsilyl-N-butoxycarbonylprop-2-ynylamine (5) are presented.